Observational studyBMC infectious diseases2022
Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation.
Observational study in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.JCI insight · 2025Trial
- Standardized Brazilian green propolis extract (EPP-AF®) in COVID-19 outcomes: a randomized double-blind placebo-controlled trial.Scientific reports · 2023Trial
- Genomic surveillance of SARS-CoV-2: a resource-efficient wastewater-based workflow.Molecular biology reports · 2026Article
- Immunological Mechanisms and Machine Learning Applications in Post-COVID-19 Syndrome: A Narrative Review.Microorganisms · 2026Article
- Myeloid Cell States in Influenza-Associated Pulmonary Aspergillosis Are Shaped by Iron Overload and Metabolic Reprogramming.bioRxiv : the preprint server for biology · 2026Article
- Viral genotype and the pace of epidemic waves: an assessment from SARS-CoV 2 genomics and wastewater surveillance data.Archives of virology · 2026Article
- Segmented filamentous bacteria reprogramming of alveolar macrophages limits postinfluenza bacterial pneumonia.Science immunology · 2026Article
- Article
- Mechanisms of Interleukin-10-Mediated Immunosuppression in Viral Infections.Pathogens (Basel, Switzerland) · 2025Review
- Association of Extended Steroid Treatment With Bloodstream Infection in Critically Ill Patients With COVID-19: A National, Multicenter, Propensity Score-Matched Study.Journal of Korean medical science · 2025Article
- Development of a risk prediction model for secondary infection in severe/critical COVID-19 patients.BMC infectious diseases · 2025Article
- The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.eLife · 2025Observational
- Procalcitonin Level and Antimicrobial Resistance among Microbial Coinfection in Hospitalized COVID-19 Patients.Reports of biochemistry & molecular biology · 2025Article
- Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.Computational and structural biotechnology journal · 2025Review
- Treatment with proton pump inhibitors is associated with secondary bacterial infections and sepsis in patients with COVID-19: a retrospective analysis of their joint impact on in-hospital prognosis.Annals of medicine · 2024Article
- Co-infections and secondary infections amid COVID-19 outbreaks in Vietnam.BMC infectious diseases · 2024Article
- Relative frequencies and clinical features of Guillain-Barré Syndrome before and during the COVID-19 pandemic in North China.BMC infectious diseases · 2024Article
- Characterization of genes related to the efflux pump and porin in multidrug-resistant Escherichia coli strains isolated from patients with COVID-19 after secondary infection.BMC microbiology · 2024Article
- Immunometabolic features of natural killer cells are associated with infection outcomes in critical illness.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients infected with severe acute respiratory syndrome coronavirus (SARS-CoV-2) can develop severe illness necessitating intensive care admission. Critically ill patients are susceptible for the development of secondary bacterial infections. Due to a combination of virus- and drug-induced immunosuppression, critically ill patients with corona virus disease 2019 (COVID-19) may even have a higher risk of developing a secondary infection. These secondary infections can aggravate the severity of illness and increase the risk of death. Further research on secondary infections in COVID-19 patients is essential. Therefore, the objective of this study was to investigate the incidence and associated risk factors of secondary bacterial infections and to identify the most common groups of pathogens in critically ill COVID-19 patients.
methodsThis mono-center, retrospective observational cohort study was performed at the intensive care unit (ICU) of the Jessa Hospital, Hasselt, Belgium. All adult COVID-19 patients admitted to the ICU from 13th March 2020 until 17th October 2020, were eligible for inclusion in the study. Data from the resulting 116 patients were prospectively entered into a customized database. The resulting database was retrospectively reviewed to investigate three types of secondary bacterial infections (secondary pneumonia, bloodstream infections of unknown origin, catheter-related sepsis).
resultsOf 94 included patients, 68% acquired at least one of the studied secondary bacterial infections during their ICU stay. Almost two thirds of patients (65.96%, n = 62) acquired a secondary pneumonia, whereas 29.79% (n = 28) acquired a bacteremia of unknown origin and a smaller proportion of patients (14.89%, n = 14) acquired a catheter-related sepsis. Male gender (P = 0.05), diabetes mellitus (P = 0.03) and the cumulative dose of corticosteroids (P = 0.004) were associated with increased risk of secondary bacterial infection. The most common pathogens detected in the cultures of patients with secondary pneumonia were Gram-negative bacilli. Bacteremia of unknown origin and catheter-related sepsis were mostly caused by Gram-positive cocci.
conclusionThis study confirms that the incidence of secondary bacterial infections is very high in critically ill COVID-19 patients. These patients are at highest risk of developing secondary pneumonia. Male gender, a history of diabetes mellitus and the administration of corticosteroids were associated with increased risk of secondary bacterial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.